Global Antisense & RNAi Therapeutics Market 2026–2030: Forecast Insights for Business Planning
Uncover key drivers, emerging technologies, and competitive movements shaping the antisense & rnai therapeutics market from 2026–2035 with trusted insights from The Business Research Company
What growth pattern is forecast for the Antisense & RNAi Therapeutics Market size between 2026 and 2035?
The antisense & rnai therapeutics market size has observed substantial growth in recent years. It is forecast to rise from $1.93 billion in 2025 to $2.17 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.6%. The expansion witnessed in previous periods is attributable to factors such as the early adoption of antisense therapies, initial RNAi research breakthroughs, the advancement of oligonucleotide synthesis techniques, a growing demand for targeted therapeutics, and investments in biotech research.
The antisense & rnai therapeutics market is projected to experience swift expansion in the coming years, anticipated to reach a valuation of $3.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.9%. Key drivers for this growth during the forecast period include progress in delivery technologies, the broadening scope of precision medicine, the incorporation of AI in drug discovery, a rise in RNAi-based clinical trials, and increased healthcare investments within emerging markets. Significant trends expected in the same period encompass targeted gene silencing, innovative delivery mechanisms, personalized therapeutic approaches, techniques for nucleic acid stabilization, and ongoing regulatory and clinical advancements.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp
Which Drivers Are Impacting Market Performance In The Antisense & RNAi Therapeutics Market?
The anticipated increase in the incidence of coronary artery diseases, neurodegenerative conditions, and infectious diseases is expected to fuel the need for the antisense & RNAi therapeutics market. Gene suppression methods, such as RNA interference and antisense oligonucleotides, offer treatment for various neurodegenerative ailments through the correction of mutant genes. For example, a report from the American Heart Association, a US-based organization, indicated that in January 2024, the age-adjusted mortality rate for cardiovascular diseases climbed to 233.3 per 100,000, signifying a 4.0% increase compared to the prior year. Consequently, the expanding occurrence of numerous neurodegenerative and infectious diseases is set to propel the expansion of the antisense & RNAi therapeutics market.
Which Segments Are Contributing To The Growth Of The Antisense & RNAi Therapeutics Market?
The antisense & rnai therapeutics market covered in this report is segmented –
1) By Technology: RNA Interference, Antisense RNA
2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics
2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides
What Long-Term Trends Are Expected To Shape The Future Of The Antisense & RNAi Therapeutics Market?
Leading companies operating within the antisense & RNAi therapeutics market are implementing strategic initiatives, such as collaborations and partnerships, to maintain their standing in the increasingly competitive landscape. Strategic collaboration is a business approach involving two or more entities working together to achieve a shared goal or objective. For instance, in January 2023, Orbit Discovery Limited, a US-based company providing services for peptide discovery, collaborated with SanegeneBio Inc., a UK-based firm focused on developing novel RNAi-based medicines. This partnership aims to identify tissue-specific delivery methods for RNA therapeutics to enable efficient gene knockdown, with the ultimate goal of developing a portfolio of advanced RNAi therapeutics. The collaboration includes hit identification and cell-based internalization studies, granting Sanegene the option to further develop the hits derived from these screening activities by leveraging Orbit’s proprietary technology for rapid peptide lead discovery. Orbit Discovery’s unique peptide display engine allows for the screening of large peptide libraries, contributing to faster discovery times for relevant peptide leads based on affinity and functional screens.
Who Are The Primary Competitors In The Global Antisense & RNAi Therapeutics Market?
Major companies operating in the antisense & rnai therapeutics market are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical
Access The Complete Report For Deeper Market Insights:
Which Global Regions Are Shaping The Competitive Landscape Of The Antisense & RNAi Therapeutics Market?
North America was the largest region in the antisense & RNAi therapeutics market in 2025. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Antisense & RNAi Therapeutics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp
Browse Through More Reports Similar to the Global Antisense & RNAi Therapeutics Market 2026, By The Business Research Company
Antisense And Rnai Therapeutics Market Report 2026
Rna Targeting Small Molecules Therapeutics Market Report 2026
Mrna Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
